Cargando…
Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)
BACKGROUND: Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of e...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503089/ https://www.ncbi.nlm.nih.gov/pubmed/37715133 http://dx.doi.org/10.1186/s12885-023-11390-4 |
_version_ | 1785106449427333120 |
---|---|
author | Xie, Lu Liang, Xin Xu, Jie Sun, Xin Liu, Kuisheng Sun, Kunkun Li, Yuan Tang, Xiaodong Li, Xianan Zhan, Xing Niu, Xiaohui Guo, Wei |
author_facet | Xie, Lu Liang, Xin Xu, Jie Sun, Xin Liu, Kuisheng Sun, Kunkun Li, Yuan Tang, Xiaodong Li, Xianan Zhan, Xing Niu, Xiaohui Guo, Wei |
author_sort | Xie, Lu |
collection | PubMed |
description | BACKGROUND: Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of extracellular matrix. This study evaluated the efficacy and safety of the anti-PD-L1/TGF-β antibody TQB2858 in patients with refractory osteosarcoma and alveolar soft part sarcoma (ASPS). METHODS: This single-arm phase 1b exploratory study included patients with refractory osteosarcoma or ASPS who had previously undergone at least two lines of systemic therapy. Patients were administered 1200 mg of TQB2858 once every 3 weeks. The primary endpoint was objective response rate (ORR), with null and alternative hypotheses of ORR ≤5% and ≥20%, respectively. Exploratory biomarker analyses using immunohistochemistry (IHC) staining (for PD-L1 and TGF-β) were performed on pre-treatment tumor samples. RESULTS: Eleven eligible patients were included in this study. TQB2858 did not demonstrate evidence of efficacy as 0/5 osteosarcomas had any objective response, while 2/6 ASPS showed a partial response. The median progression-free survivals were 1.51 (1.38, Not Evaluable) and 2.86 (1.38, Not Evaluable) months for the osteosarcoma and ASPS groups, respectively. None of the administered cycles met the criteria for unacceptable toxicity. Other Grade 3 toxicities included abnormal liver function and elevation of γ-glutamyl transferase. IHC analysis revealed that functional enrichment in the TGF-β pathway or PD-L1 was not associated with treatment outcomes. CONCLUSIONS: The combination of PD-L1 and TQB2858 did not significantly improve the ORR in patients with recurrent osteosarcoma. However, it improved immunogenic responses in ASPS, even after progression upon anti-PD-1/PD-L1 therapy, with an acceptable safety profile. IHC profiling with pathway enrichment analysis may not have any predictive value for survival outcomes. TRIAL REGISTRATION: Prospectively registered in the Ethical Review Committee of Peking University People’s Hospital. The trial registration number is 2021PHA105-001 and 2021PHA140-001 and the registration date was March 2, 2022. ClinicalTrials.gov Identifier CTR20213001 and CTR20220390 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11390-4. |
format | Online Article Text |
id | pubmed-10503089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105030892023-09-16 Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) Xie, Lu Liang, Xin Xu, Jie Sun, Xin Liu, Kuisheng Sun, Kunkun Li, Yuan Tang, Xiaodong Li, Xianan Zhan, Xing Niu, Xiaohui Guo, Wei BMC Cancer Research BACKGROUND: Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of extracellular matrix. This study evaluated the efficacy and safety of the anti-PD-L1/TGF-β antibody TQB2858 in patients with refractory osteosarcoma and alveolar soft part sarcoma (ASPS). METHODS: This single-arm phase 1b exploratory study included patients with refractory osteosarcoma or ASPS who had previously undergone at least two lines of systemic therapy. Patients were administered 1200 mg of TQB2858 once every 3 weeks. The primary endpoint was objective response rate (ORR), with null and alternative hypotheses of ORR ≤5% and ≥20%, respectively. Exploratory biomarker analyses using immunohistochemistry (IHC) staining (for PD-L1 and TGF-β) were performed on pre-treatment tumor samples. RESULTS: Eleven eligible patients were included in this study. TQB2858 did not demonstrate evidence of efficacy as 0/5 osteosarcomas had any objective response, while 2/6 ASPS showed a partial response. The median progression-free survivals were 1.51 (1.38, Not Evaluable) and 2.86 (1.38, Not Evaluable) months for the osteosarcoma and ASPS groups, respectively. None of the administered cycles met the criteria for unacceptable toxicity. Other Grade 3 toxicities included abnormal liver function and elevation of γ-glutamyl transferase. IHC analysis revealed that functional enrichment in the TGF-β pathway or PD-L1 was not associated with treatment outcomes. CONCLUSIONS: The combination of PD-L1 and TQB2858 did not significantly improve the ORR in patients with recurrent osteosarcoma. However, it improved immunogenic responses in ASPS, even after progression upon anti-PD-1/PD-L1 therapy, with an acceptable safety profile. IHC profiling with pathway enrichment analysis may not have any predictive value for survival outcomes. TRIAL REGISTRATION: Prospectively registered in the Ethical Review Committee of Peking University People’s Hospital. The trial registration number is 2021PHA105-001 and 2021PHA140-001 and the registration date was March 2, 2022. ClinicalTrials.gov Identifier CTR20213001 and CTR20220390 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11390-4. BioMed Central 2023-09-15 /pmc/articles/PMC10503089/ /pubmed/37715133 http://dx.doi.org/10.1186/s12885-023-11390-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Xie, Lu Liang, Xin Xu, Jie Sun, Xin Liu, Kuisheng Sun, Kunkun Li, Yuan Tang, Xiaodong Li, Xianan Zhan, Xing Niu, Xiaohui Guo, Wei Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) |
title | Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) |
title_full | Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) |
title_fullStr | Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) |
title_full_unstemmed | Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) |
title_short | Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02) |
title_sort | exploratory study of an anti-pd-l1/tgf-β antibody, tqb2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from chinese sarcoma study group (tqb2858-ib-02) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503089/ https://www.ncbi.nlm.nih.gov/pubmed/37715133 http://dx.doi.org/10.1186/s12885-023-11390-4 |
work_keys_str_mv | AT xielu exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT liangxin exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT xujie exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT sunxin exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT liukuisheng exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT sunkunkun exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT liyuan exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT tangxiaodong exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT lixianan exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT zhanxing exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT niuxiaohui exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 AT guowei exploratorystudyofanantipdl1tgfbantibodytqb2858inpatientswithrefractoryorrecurrentosteosarcomaandalveolarsoftpartsarcomaareportfromchinesesarcomastudygrouptqb2858ib02 |